The FDA has, for the first time, proactively developed and tested a product label to encourage development of an over-the-counter version of the opioid overdose antidote naloxone, according to an agency statement.
The agency’s action removes the burden from the companies of creating such labels and conducting studies that show consumers can use a product without a health care professional’s supervision.
This activity is supported by an educational grant from Indivior, Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.